Recombinant protein therapeutics CDMO Market, By Type (Growth hormones, Interferons, Vaccines, and Immunostimulant agents), By Indication, By Source, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
REPORT HIGHLIGHT
Recombinant protein therapeutics CDMO Market size was valued at USD 20,920.32 Million in 2024, expanding to a CAGR of 13.98% from 2025 to 2032.
A Recombinant Protein Therapeutics CDMO specializes in providing services for the development, production, and scaling of protein-based drugs, catering to biotech and pharmaceutical companies. These organizations support the entire process, from cell line development and upstream to downstream processing, analytical testing, regulatory compliance, and large-scale manufacturing.
Recombinant protein therapeutics CDMO Market- Market Dynamics
Ø Rising Demand for Biologics and Advancements in Bioprocessing Technologies Set to Drive Market Growth
The growth of the recombinant protein therapeutics CDMO market is largely fueled by the rising demand for biologic drugs and the increasing complexity associated with their production. As the pharmaceutical and biotech sectors face these challenges, many companies are turning to specialized CDMOs for support. Additionally, the increasing market acceptance of biosimilars—cost-effective alternatives to original biologics—is further driving the demand for CDMO services in the production of recombinant proteins. This trend is significantly contributing to market expansion. Technological advancements such as the use of single-use bioreactors, continuous manufacturing methods, and high-yield expression systems (including CHO and HEK293 cells) have greatly improved the efficiency of protein production. Furthermore, innovations in both upstream and downstream processing have led to better protein yields, thereby reducing production costs and timelines.
According to the U.S. Food and Drug Administration (FDA), the number of biologics approved annually has steadily increased, with 60 biologics approved in 2021 alone. This surge in biologic approvals underscores the growing reliance on CDMOs to meet production demands. Similarly, market reports estimate that the global biologics market is expected to surpass USD 500 billion by 2025, signaling a continued need for advanced manufacturing solutions such as those provided by CDMOs. The growing focus on personalized medicine and precision therapeutics has led to an increased demand for customized recombinant proteins. Recombinant protein-based cell and gene therapies are expanding the role of CDMOs in the development of advanced biologics. Additionally, the rise of new applications in oncology, rare diseases, and regenerative medicine is driving market growth. The Asia-Pacific region, especially China, India, and South Korea, is emerging as a key hub for biopharmaceutical manufacturing due to lower production costs and supportive government policies. As a result, many CDMOs are establishing facilities in these countries to meet the rising demand for affordable biologic treatments.
Recombinant protein therapeutics CDMO Market- Segmentation Analysis:
The Global Recombinant protein therapeutics CDMO Market is segmented on the basis of Type, Indication, Source, and Region.
The recombinant protein therapeutics market is divided into five key categories based on type: growth hormones, interferons, vaccines, immunostimulant agents, and others. Among these, the interferons segment dominates the market, primarily due to the increasing prevalence of infectious diseases, including viral infections and certain cancers, which are driving the demand for interferon-based treatments. According to the U.S. Centers for Disease Control and Prevention (CDC), viral diseases such as hepatitis C and influenza are among the leading causes of morbidity and mortality worldwide, creating a strong demand for therapeutic interventions such as interferons. Moreover, the global trend toward personalized medicine and the development of new interferon-based biologics are expected to further fuel segment growth in the coming years.
The market is also segmented based on indication into oncology, infectious diseases, immunological disorders, metabolic disorders, hematological disorders, and others. The \"others\" category is anticipated to hold the largest share, driven by the broad spectrum of indications covered by recombinant protein therapeutics, including rare and orphan diseases. Among the various indications, the metabolic disorders segment is expected to grow at the fastest rate over the forecast period. This growth is attributed to the rising incidence of metabolic conditions such as diabetes, obesity, and rare genetic metabolic disorders. According to the World Health Organization (WHO), the global prevalence of diabetes has nearly quadrupled over the past few decades, further driving demand for recombinant protein therapeutics designed to manage such diseases.
The market is further categorized by the source of the recombinant proteins: mammalian systems, microbial systems, and others. The mammalian systems segment holds the largest share, primarily due to the higher production yields and post-translational modifications that mammalian cells provide, making them ideal for producing complex therapeutic proteins. The demand for mammalian-based recombinant proteins has been steadily increasing, driven by advancements in genetic engineering, biopharmaceuticals, and the growing emphasis on biologics. According to the U.S. Food and Drug Administration (FDA), over 30 biologic therapies currently approved for clinical use are produced using mammalian cell lines, with continued investments in this technology projected to boost future growth.
Recombinant protein therapeutics CDMO Market- Geographical Insights
In terms of geographical distribution, the recombinant protein therapeutics contract development and manufacturing organization (CDMO) market spans across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a dominant position in this market, led by the United States, which is a global leader in recombinant protein production. The U.S. has established a robust biopharmaceutical infrastructure, supported by substantial investments in research and development, contributing to the rapid commercialization of recombinant protein therapeutics. The National Institutes of Health (NIH) reports that the U.S. is home to the largest number of clinical trials for biopharmaceuticals, including those based on recombinant proteins. Meanwhile, the Asia-Pacific region is witnessing rapid growth, spurred by increasing healthcare expenditures, a rising incidence of chronic diseases, and significant investments in biotechnology and biomanufacturing. According to a 2023 report by the Asian Development Bank (ADB), the Asia-Pacific region\'s healthcare market is expected to grow at a compound annual growth rate (CAGR) of 9.4%, providing substantial opportunities for recombinant protein therapeutics. The Middle East and Africa are also showing moderate growth, driven by improved healthcare infrastructure and expanding access to advanced treatments, but the region is still in the early stages of market development.
Recombinant protein therapeutics CDMO Market- Competitive Landscape:
The recombinant protein therapeutics CDMO market is highly competitive, with several major players working to improve their service offerings and broaden their market presence. These companies provide a wide range of services for the development and manufacturing of biopharmaceuticals, including recombinant proteins. Some specialize in the production of therapeutic proteins, offering end-to-end solutions from cell line development to commercial-scale production.
Recent Developments:
v In 2024, Novo Holdings announced a USD 16.5 billion acquisition of Catalent, aiming to enhance its production capabilities for its popular weight-loss medications.
v In June 2023, Richter-Helm BioLogics revealed plans to develop a new production facility in Bovenau, Europe, further strengthening its manufacturing capacity.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET KEY PLAYERS
Ø Richter-Helm BioLogics
Ø Lonza
Ø Catalent, Inc
Ø FUJIFILM Diosynth Biotechnologies
Ø WuXi Biologics
Ø Curia Global, Inc.
Ø Batavia Biosciences B.V.
Ø AGC Biologics
Ø Boehringer Ingelheim BioXcellence
Ø Repligen Corporation
Ø Therapure BioPharma Inc.
Ø Cytovance Biologics
Ø KBI Biopharma
Ø Abzena
Ø Patheon
Ø Others
GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY TYPE- MARKET ANALYSIS, 2019-2032
Ø Growth hormones
Ø Interferons
Ø Vaccines
Ø Immunostimulant agents
Ø Others
GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY INDICATION- MARKET ANALYSIS, 2019-2032
Ø Oncology
Ø Infectious Diseases
Ø Immunological disorders
Ø Metabolic disorders
Ø Hematological disorders
Ø Others
GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY SOURCE- MARKET ANALYSIS, 2019-2032
Ø Mammalian system
Ø Microbial systems
Ø Others
GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019-2032
Ø North America
o The U.S.
o Canada
Ø Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Russia
o Netherlands
o Sweden
o Poland
o Rest of Europe
Ø Asia Pacific
o India
o China
o South Korea
o Japan
o Australia
o Thailand
o Indonesia
o Philippines
o Rest of APAC
Ø Latin America
o Brazil
o Mexico
o Argentina
o Colombia
o Rest of LATAM
Ø The Middle East and Africa
o Saudi Arabia
o UAE
o Israel
o Turkey
o Algeria
o Egypt
o Rest of MEA
TABLE OF CONTENT
1. Recombinant Protein Therapeutics CDMO Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Recombinant Protein Therapeutics CDMO Market Snippet by Type
2.1.2. Recombinant Protein Therapeutics CDMO Market Snippet by Indication
2.1.3. Recombinant Protein Therapeutics CDMO Market Snippet by Source
2.1.4. Recombinant Protein Therapeutics CDMO Market Snippet by Country
2.1.5. Recombinant Protein Therapeutics CDMO Market Snippet by Region
2.2. Competitive Insights
3. Recombinant Protein Therapeutics CDMO Key Market Trends
3.1. Recombinant Protein Therapeutics CDMO Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Recombinant Protein Therapeutics CDMO Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Recombinant Protein Therapeutics CDMO Market Opportunities
3.4. Recombinant Protein Therapeutics CDMO Market Future Trends
4. Recombinant Protein Therapeutics CDMO Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Recombinant Protein Therapeutics CDMO Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Recombinant Protein Therapeutics CDMO Market Landscape
6.1. Recombinant Protein Therapeutics CDMO Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Recombinant Protein Therapeutics CDMO Market – By Type
7.1. Overview
7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
7.1.2. Growth hormones
7.1.3. Interferons
7.1.4. Vaccines
7.1.5. Immunostimulant agents
7.1.6. Others
8. Recombinant Protein Therapeutics CDMO Market – By Indication
8.1. Overview
8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
8.1.2. Oncology
8.1.3. Infectious Diseases
8.1.4. Immunological disorders
8.1.5. Metabolic disorders
8.1.6. Hematological disorders
8.1.7. Others
9. Recombinant Protein Therapeutics CDMO Market – By Source
9.1. Overview
9.1.1. Segment Share Analysis, By Source, 2024 & 2032 (%)
9.1.2. Mammalian system
9.1.3. Microbial systems
9.1.4. Others
10. Recombinant Protein Therapeutics CDMO Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.9.5. France Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3.16. Rest of Europe
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.16.5. Rest of the Europe Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.6. APAC Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.7.5. China Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.8.5. India Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.6. MEA Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Recombinant Protein Therapeutics CDMO Industry
11.1. Competitive Dashboard
11.1.1. Competitive Benchmarking
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. Richter-Helm BioLogics
11.2.2. Lonza
11.2.3. Catalent, Inc
11.2.4. FUJIFILM Diosynth Biotechnologies
11.2.5. WuXi Biologics
11.2.6. Curia Global, Inc.
11.2.7. Batavia Biosciences B.V.
11.2.8. AGC Biologics
11.2.9. Boehringer Ingelheim BioXcellence
11.2.10. Repligen Corporation
11.2.11. Therapure BioPharma Inc.
11.2.12. Cytovance Biologics
11.2.13. KBI Biopharma
11.2.14. Abzena
11.2.15. Patheon
11.2.16. Others
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
